Isomorphic Labs, the London-based, drug discovery–focused spinout of Google AI R&D division DeepMind, today announced that it’s entered into strategic partnerships with two pharmaceutical giants, Eli ...
TOKYO--(BUSINESS WIRE)--Elix, Inc. (CEO: Shinya Yuki / Headquarters: Tokyo; hereinafter “Elix”) is pleased to announce that its AI drug discovery platform, Elix ...
Artificial intelligence (AI)-based drug developer Isomorphic Labs said it has raised $600 million in its first external funding round, with the proceeds expected to accelerate its research and ...
Discover what the next wave of AI-assisted drug discovery looks like and how it can help biotech - the AI and physics combo.
In developing drugs using a platform that joins physics with machine learning, Schrödinger sees more than a passing resemblance to the studio whose Toy Story and other computer-generated movies ...
The rise of AMR in pathogenic bacteria poses serious challenges to the control and management of infectious diseases. Globally, the rise of antimicrobial ...
In a recent study published in the journal Science Advances, researchers in Sweden conducted virtual screens of over 16 million compounds using multiple receptor models developed by AlphaFold and ...
This process is costly, time-consuming, and has a low success rate. KAIST researchers have developed an AI model that, using only information about the target protein, can design optimal drug ...
As soon as pharmaceutical companies recognized the potential of artificial intelligence tools for drug discovery, they rushed in with big money. After all, traditional drug discovery methods are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback